Key facts
- It has raised $19.3M; the latest was Accelerator/Incubator in Jan 2024.
- Notable investors include Innovate UK, London & Partners., Future Planet Capital, Cambridge Angels, UK Innovation & Science Seed Fund — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for MFX
- ·The full record, as it builds
Funding rounds
No funding rounds for MFX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MFX
Operator of cell therapy research and manufacturing platform designed to make bio-processing scalable and affordable for cell and gene therapy. The company's platform specializes in tackling the problems of process control and scalability with cell bioprocessing in particular for autologous cell and gene therapy, enabling biologists to carry out process development by running cell culture conditions in parallel with extreme process control and to scale up cells for manufacturing at a lower cost.
- Sector
- Healthcare
- HQ
- Stevenage, United Kingdom
- Founded
- 2018
- Employees
- 41
- Website
- mfx.bio/
- Ownership
- Privately Held (backing)
MFX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MFX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MFX in its N-PORT filings yet. We sweep new filings monthly.